Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 583-587 , October 2009

Editorial and introduction: new developments in paediatric rheumatic diseases

  • C. Wallace (Professor of Pediatrics)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 987 2057; Fax: +1 206 987 5060.

References 

  1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991–1994
  2. Stéphan JL, Zeller J, Hubert P, et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11(4):451–456
  3. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–1486
  4. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol. 2005;17(5):586–599
  5. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol. 2006;18(1):108–117
  6. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621–668
  7. Neven B, Callebaut I, Prieur AM, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood. 2004;103:2809–2815
  8. Frenkel J, Houten SM, Waterham HR, et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford). 2001;40(5):579–584
  9. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–144
  10. Ayaz NA, Ozen S, Bilginer Y, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48(1):23–25
  11. Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr. 1999;135(1):98–101
  12. Prakken B, Albani S. Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis. Arthritis Rheum. 2007;56(2):389–392
  13. Lovell DJ, Giannini EH, Reiff A, et al. Efficacy and safety of entanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–769
  14. Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting IL-1 inhibitor, in Systemic Juvenile Idiopathic Arthritis (SJIA). Arthritis Rheum. 2006;54(Suppl.):S325–S326
  15. Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol. 2001 Jun;54(6):550–557
  16. Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol. 2004;16:566–570
  17. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009 Feb;36(2):323–329
  18. Seshadri R, Feldman BM, Ilowite N, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59(7):989–995
  19. Ruperto N, Meiorin S, Mirela Lusan S, et al. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep. 2008;10:142–146
  20. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–1209

PII: S1521-6942(09)00077-1

doi: 10.1016/j.berh.2009.07.005

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 583-587 , October 2009

Article Tools